Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
Recruiting · NCT06765252 · Observational (researchers observe without assigning treatment) · Lead sponsor: Ain Shams University
View the official record on ClinicalTrials.gov →Interventions studied
Capecitabine-based chemotherapy
What this trial is about
The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with breast or colorectal cancer receiving capecitabine-based chemotherapy
- Age \> 18 years
- ECOG PS 0-2.
Exclusion criteria
- Patients treated with irinotecan
- Lack of physical integrity of the upper gastrointestinal tract
- Patients with malabsorption syndrome
- Patients having inability to take oral medication
- Patients with poor performance status
- Patients with chronic diarrhea as ulcerative colitis or Crohn's disease
Where it is running
1 location listed.
- Department of Clinical Oncology, Faculty of Medicine, Menoufia University - Shibīn al Kawm, Menoufia, Egypt